NIH R01 · 2024
Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy
Project Abstract Multiple myeloma (MM), a cancer of plasma cells that colonize the bone marrow (BM), remains incurable despite the use of new promising treatment modalities. This is partly due to (i) MM progression and drug resistance development, (ii) protection of MM cells by the BM microenvironment (BMME), and (iii) immune evasion. Thus, there is urgent need for innovative and more effective therapies, particularly for patients with advanced disease refractory to conventional agents. MicroRNAs (miRs) play critical roles in the initiation, progression, and drug resistance of various human cancer types, including MM, and are providing exciting opportunities in our ongoing search for novel…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.